Email updates

Keep up to date with the latest news and content from Retrovirology and BioMed Central.

Open Access Research

Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complex

Sebastian Biglione15, Sarah A Byers16, Jason P Price2, Van Trung Nguyen4, Olivier Bensaude4, David H Price13 and Wendy Maury12*

Author Affiliations

1 Interdisciplinary Molecular and Cellular Biology Program, University of Iowa, Iowa City, IA, USA

2 Department of Microbiology, University of Iowa, Iowa City, IA, USA

3 Department of Biochemistry, University of Iowa, Iowa City, IA, USA

4 Laboratoire de Regulation de l'Expression Genetique, Ecole Normale Superieure, Paris, France

5 CBR Institute for Biomedical Research, Harvard Medical School, Boston, MA, 02115, USA

6 Oregon Health & Science University, Department of Molecular and Medical Genetics, Portland, OR 97239, USA

For all author emails, please log on.

Retrovirology 2007, 4:47  doi:10.1186/1742-4690-4-47

Published: 11 July 2007

Abstract

Background

The positive transcription elongation factor, P-TEFb, comprised of cyclin dependent kinase 9 (Cdk9) and cyclin T1, T2 or K regulates the productive elongation phase of RNA polymerase II (Pol II) dependent transcription of cellular and integrated viral genes. P-TEFb containing cyclin T1 is recruited to the HIV long terminal repeat (LTR) by binding to HIV Tat which in turn binds to the nascent HIV transcript. Within the cell, P-TEFb exists as a kinase-active, free form and a larger, kinase-inactive form that is believed to serve as a reservoir for the smaller form.

Results

We developed a method to rapidly quantitate the relative amounts of the two forms based on differential nuclear extraction. Using this technique, we found that titration of the P-TEFb inhibitors flavopiridol, DRB and seliciclib onto HeLa cells that support HIV replication led to a dose dependent loss of the large form of P-TEFb. Importantly, the reduction in the large form correlated with a reduction in HIV-1 replication such that when 50% of the large form was gone, HIV-1 replication was reduced by 50%. Some of the compounds were able to effectively block HIV replication without having a significant impact on cell viability. The most effective P-TEFb inhibitor flavopiridol was evaluated against HIV-1 in the physiologically relevant cell types, peripheral blood lymphocytes (PBLs) and monocyte derived macrophages (MDMs). Flavopiridol was found to have a smaller therapeutic index (LD50/IC50) in long term HIV-1 infectivity studies in primary cells due to greater cytotoxicity and reduced efficacy at blocking HIV-1 replication.

Conclusion

Initial short term studies with P-TEFb inhibitors demonstrated a dose dependent loss of the large form of P-TEFb within the cell and a concomitant reduction in HIV-1 infectivity without significant cytotoxicity. These findings suggested that inhibitors of P-TEFb may serve as effective anti-HIV-1 therapies. However, longer term HIV-1 replication studies indicated that these inhibitors were more cytotoxic and less efficacious against HIV-1 in the primary cell cultures.